Navigation Links
Hikma CEO Interviewed on Half-Year 2011 Results
Date:8/25/2011

LONDON, August 25, 2011 /PRNewswire/ --

Hikma Pharmaceuticals reports lower-than-expected 3.2% increase in revenues for the first half but maintains its full-year outlook.

The international drug developer says that political unrest in the MENA region disrupted month-on-month sales in some key countries like Egypt and Tunisia.

In an interview with financial broadcaster http://www.cantos.com, Hikma CEO Said Darwazah says that production is back to normal and that in spite of difficulties the group managed to grow the business organically by 3% in the MENA region.

While the group's Multi-Source Injectables division, which was acquired from Baxter Healthcare last year, was impacted by transaction delays, Mr Darwazah remains confident the business "will be breaking even" by the fourth quarter.

Hikma's CEO also makes clear that further acquisitions in emerging markets are in the pipeline.  In the interview he reiterates full-year guidance of 7% organic growth and 20% overall business growth.

The interview and transcript are available now on http://www.cantos.com/company/Hikma%20Pharmaceuticals.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-(0)207-936-1372.



'/>"/>
SOURCE Hikma Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. HIKMA - 2008 Preliminary Results Interview With CEO
2. Hikma - Half Year Results Interviews With CEO and CFO
3. Hikma Expands its Global Injectables Business - Live Webcast
4. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
5. China Sky One Medical, Inc. Interviewed in The China Perspective
6. Access Pharmaceuticals CEO Interviewed on Financial Website
7. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
8. Cord Blood America CEO Matthew Schissler Interviewed on International Successes
9. Smith & Nephew CEO Interviewed on Q2 2011 Results
10. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
11. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... BOSTON , Feb. 9, 2016 ... a data-driven, biological research approach, has announced the ... Financial Officer and Chief Operating Officer. Haddock brings ... corporate finance, including 12 years in senior financial ... global experience in business organizational management. ...
(Date:2/8/2016)... 8, 2016 --> ... an innovation-driven oncology company developing next generation cancer ... today announced that chairman emeritus of Tata Sons ... the company as part of the first close ... investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)... ... 2016 , ... Bulk food product inspection systems are specifically ... of the production process. Despite frequently inspecting loose product prior to packaging, product ... as sacks of dry powders. , Mettler-Toledo Product Inspection's brand-new white paper entitled ...
(Date:2/8/2016)... BATH, England , February 8, 2016 ... Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care ... approval to CE Mark its Chlamydia trachomatis (CT) test to ... requirements of the IVD Directive (98/79/EC), the CT test is ... --> --> The launch of the ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):